Despite widespread implementation of the 21-gene test, some minorities and Medicaid patients have less access to testing. We also identified patients for whom the appropriateness of testing was questionable due to comorbid medical conditions or advanced age. Our data illustrate the need to improve coding to ensure that reimbursement of genomic tests is tied to appropriate use and to discourage overutilization.
Utilization of the 21-Gene Rs Test Among Medicare Beneficiaries with Breast Cancer in 2011 [MEETING ABSTRACT PCN177]
Lynch, J., Berse, B., Coomer, N., & Kautter, J. (2016). Utilization of the 21-Gene Rs Test Among Medicare Beneficiaries with Breast Cancer in 2011 [MEETING ABSTRACT PCN177]. Value in Health, 19(3), A165-A165. https://doi.org/10.1016/j.jval.2016.03.1510
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Community overdose surveillance
Epigenetic biomarkers for smoking cessation